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Objective. To determine the efficacy and safety of high dose dexmedetomidine as a sole sedative agent for MRI. We report our
institution’s experience. Design. A retrospective institutional review of dexmedetomidine usage for pediatric MRI over 5.5 years.
Protocol included a dexmedetomidine bolus of 2 𝜇g/kg intravenously over tenminutes followed by 1𝜇g/kg/hr infusion. 544 patients
received high dose dexmedetomidine for MRI. A second bolus was used in 103 (18.9%) patients. 117 (21.5%) required additional
medications. Efficacy, side effects, and use of additional medicines to complete the MRI were reviewed. Data was analyzed using
Student’s t-test, Fisher’s exact test, and Analysis of Variance (ANOVA). Main Results. Dexmedetomidine infusion was associated
with bradycardia (3.9%) and hypotension (18.4%). None of the patients required any intervention. Vital signs were not significantly
different among the subgroup of patients receiving one or two boluses of dexmedetomidine or additional medications. Procedure
timewas significantly shorter in the group receiving only one dexmedetomidine bolus and increasedwith second bolus or additional
medications (𝑃 < 0.0001). Discharge time was longer for children experiencing bradycardia (𝑃 = 0.0012). Conclusion. High
dose Dexmedetomidine was effective in 78.5% of cases; 21.5% of patients required additional medications. Side effects occurred
in approximately 25% of cases, resolving spontaneously.
1. Introduction
Sedation is often required in young children in order to
obtain good diagnostic cross-sectional imaging like com-
puted tomography scan (CT scan) and magnetic resonance
imaging (MRI). Sometimes sedation is also needed for older
children with complex neurodevelopmental disorders, such
as autism and attention deficit hyperactivity disorder.Moder-
ate sedation is unable to guarantee patient compliance; there-
fore, a deeper level of sedation is required [1, 2].
The success of sedation for MRI has typically been
measured by two factors: the safety of sedation procedure
(lack of adverse events) and its effectiveness (completion of
diagnostic examination) [3].
It can be challenging to obtain the deep sedation level
required to prevent the patient’s movement while main-
taining respiratory and hemodynamic stability. Also, limited
access to the patient may pose a safety risk during MRI [4].
Therefore, it is very important to select the appropriate drugs
and dosage to achieve those objectives [5].
Dexmedetomidine is a highly selective adrenoceptor
agonist with a distribution half-life of six minutes and
an elimination half-life of two hours [6]. Its success as a
sedative agent varies depending on the dose and clinical
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situation [7]. Five prospective trials have evaluated the
efficacy of dexmedetomidine for sedation during noninva-
sive radiologic imaging [8–12]. Dexmedetomidine can be
associated with side effects of hypotension, bradycardia, and
transient hypertension with loading dose. Dexmedetomidine
has been used at our institution since 2006 for MRI and
other noninvasive radiologic procedures.The purpose of this
retrospective study is to present our institutional experience
with dexmedetomidine in relation to efficacy and related side
effects.
2. Materials and Methods
Collection of quality assurance data includes patient demo-
graphics, adverse events, physiologic variables, drug dosages,
the time required to sedate the patient, time needed to obtain
the imaging study, and recovery time. Data are entered into a
database by two designated staff members. After approval by
the Institutional Review Board, we conducted a retrospective
analysis of all patients who received sedation for MRI from
July 2007 to December 2012.
Institutional sedation policies are based on guidelines
by the Joint Commission on Accreditation of Health Care
Organization and American Academy of Pediatrics and were
closely followed [13, 14]. Vital signs including pulse oximetry,
heart rate, noninvasive blood pressure monitoring, and nasal
capnography (with concomitant oxygen delivery via the nasal
cannula) are continuously monitored and documented every
five minutes throughout sedation.
At the start of sedation, intravenous dexmedetomidine
was bolused at 2 𝜇g/kg over 10 minutes followed by a
continuous infusion of 1 𝜇g/kg/h. Most of the patients were
sedated by the end of the bolus; if not, a second bolus of
2 𝜇g/kg was repeated over another 10 minutes prior to the
start of the maintenance infusion. Patients who continue to
move after the second bolus or while the procedure is in
progress, can compromise the quality of imaging and were
given additional medications like midazolam or fentanyl as
per physician discretion. The dose range used for Versed was
0.05mg/kg–0.1mg/kg to a max of 2mg and for fentanyl was
0.5mcg/kg–1mcg/kg to a max of 50mcg.
The goal was to achieve a minimum Ramsay Sedation
Score (RSS) of 4 as assessed by a sedation nurse [15]. RSS
is a clinically derived sedation score generally accepted as a
tool for assessing the depth of sedation. Usually, a score of
4-5 is targeted to ensure appropriate sedation for diagnostic
imaging studies [11, 16]. Peak onset of the sedation was
defined as the time from the start of the loading dose to
achievement of a Ramsay score of 4. Procedure time was the
time of achieving the required Ramsay score to the end of the
procedure (stoppage of drug administration). Discharge time
was defined as time from the end of the procedure to actual
time when the patient was discharged home [17]. Normal
ranges for heart rates, blood pressure, and respiratory rates for
data analysis were based on the published normal of Fleming
et al. [17, 18].
A trained registered nurse provided continuous assess-
ment and monitoring while the procedure was in progress
Table 1: Demographic characteristics (July 2007–December 2012).
Dex A Dex B Dex C
Sex
Male 180 (55.6) 70 (68.0) 65 (55.6)
Female 144 (44.4) 33 (32.0) 52 (44.4)
Age (months) 53.74 (38.49) 55.65 (33.39) 53.60 (42.47)
Weight (kg) 19.30 (10.43) 18.45 (8.78) 19.52 (13.73)
under the direct supervision of a pediatric intensivist. Mon-
itoring was continued until the patient was awake with a
minimum Aldrete score of 9 points, and the patient has
tolerated clear liquids prior to discharge [19, 20]. All the par-
ents were provided with written discharge instructions and a
direct phone number for further assistance or to report any
adverse effects.
Database records were analyzed using dedicated sta-
tistical software SAS v9.3 (SAS Institute, Cary, NC). Data
are expressed in terms of means and standard deviations.
Changes in the vital signs associated with the use of
dexmedetomidine from the baseline were evaluated and
compared using Student’s t-test and Mann-Whitney rank-
sum test, depending on the distribution of the data. The
entire study cohort was divided into three groups depend-
ing on dexmedetomidine bolus and additional medications
received. Dexmedetomidine group A received one bolus;
dexmedetomidine group B received two boluses; dexmedeto-
midine group C received one or two boluses and additional
medications. Three groups were compared with respect to
age, weight, blood pressure, heart rate, procedure time, and
discharge time using Analysis of Variance. Incidences of
bradycardia and hypotension were analyzed with Fisher’s
exact test, due to low cell counts. Discharge time of brady-
cardia and hypotensive patients was compared with normal
cohorts using the t-test. A 𝑃 value < 0.05 was considered
statistically significant.
3. Results
544 patients were sedated using dexmedetomidine for MRI
with 100% satisfactory completion. The most common indi-
cations included seizure disorder, developmental delay and
behavioral disorder, autism, and neoplasia. Demographic
characteristic and procedure and recovery times are pre-
sented in Tables 1 and 4. No significant group difference was
found for gender, age, or weight.
382 (70.2%) of the total patients received one-time bolus,
while two boluses were given to 162 patients (29.8%). In the
population of 544 patients, additional medications (fentanyl
or midazolam) were required in 117 (21.5%) for spontaneous
movements to avoid motion artifacts that can compromise
MRI quality (54 patients with one-time bolus and 43 patients
with two boluses). Dexmedetomidine-induced vital sign
changes from baseline for the whole group are shown in
Figure 1.
Hypotension (systolic blood pressure 20% below the
normal limits) was observed in 100 patients (18.4%) and
transient hypertension (systolic blood pressure >20% above
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Table 2: Outcomes with DEX group—clinical measures.
Dex A (𝑛 = 324) Dex B (𝑛 = 103) Dex C (𝑛 = 117) 𝑃 value
Oxygen liters/min 0.87 (0.48) 0.99 (0.56) 1.20 (0.61) <0.0001∗
Dose (mcg) 35.96 (17.37) 36.20 (10.38) 26.88 (17.58) <0.0001∗
DBP (initial) 66.28 (11.54) 67.91 (10.81) 65.29 (13.63) 0.2785
DBP (vital min) 39.75 (9.10) 39.52 (8.48) 40.34 (9.34) 0.8416
DBP (vital max) 80.29 (10.94) 81.38 (10.60) 84.32 (13.61) 0.0264∗
SBP (initial) 112.50 (13.95) 111.93 (12.17) 113.10 (13.52) 0.8234
SBP (vital min) 84.61 (8.93) 83.60 (9.84) 84.91 (10.75) 0.5570
SBP (vital max) 122.66 (12.69) 122.17 (11.14) 124.78 (14.13) 0.2311
HR (initial) 99.86 (19.11) 103.16 (20.11) 101.40 (21.22) 0.3277
HR (vital min) 72.00 (13.94) 70.08 (12.49) 72.61 (14.50) 0.3559
HR (vital max) 110.69 (21.66) 111.12 (21.55) 114.97 (22.80) 0.1873
Resp. (initial) 20.45 (3.43) 20.36 (4.14) 21.24 (4.06) 0.1343
Resp. (vital min) 15.64 (4.10) 15.97 (5.42) 15.31 (4.24) 0.5413
Resp. (vital max) 24.27 (5.07) 25.84 (8.59) 26.25 (7.78) 0.00067
SPO2 (initial) 99.11 (1.14) 99.07 (1.12) 98.80 (1.40) 0.0548
Values are means (standard deviations); 𝑃 values are from ANOVAs.
MTD: time to discharge, DBP min: lowest diastolic blood pressure, DBP max: highest diastolic blood pressure, SBP min: lowest systolic blood pressure, SBP
max: highest systolic blood pressure, HR min: lowest heart rate, and HR max: highest heart rate.
∗Significant association at 𝑃 < 0.05.
Changes in vital signs from baseline
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Figure 1: Minimal andmaximal change in vital signs from baseline.
age-specific high limits) was observed in 137 of the patients
(25.2%). There were 210 (38.6%) patients who had a signif-
icant decrease in respiratory rate, that is, >20% from the
baseline, but no desaturation, upper airway obstruction, or
apnea events were observed and the decrease was minimal in
403 patients (74%).Most of the patients received prophylactic
supplemental oxygen to maintain oxygen saturation >95%
as per protocol, which makes it impossible to determine the
actual incidence of desaturation at room air.
Patientswere divided into three groups based onnumbers
of dexmedetomidine boluses and additional medications
received. Comparisons of blood pressure, heart rate, and
other clinical measures between these groups of patients are
shown in Table 2. Procedure time was significantly shorter
in dexmedetomidine group A (40.31 ± 19.40min, 𝑃 <
0.0001) compared to the other two groups. Oxygen, dose,
maximum DBP, maximum respiration rate, and initial SPO2
had statistically significant (but clinically insignificant) differ-
ences between groups.
The occurrence of hypotension among all three groups
did not reach a statistically significant value (𝑃 = 0.82).
Decrease in blood pressure from the baseline was frequently
observed; however, medical intervention was not needed
to correct it. The incidence of hypotension was usually
noticed to be towards the completion of procedure or after
stopping the infusion, with a mean procedure time of 48.73±
25.46minutes. Initial transient hypertension occurred in 137
patients approximately 20 minutes after the dexmedetomi-
dine bolus and lasted for <15 minutes.
In the population of 544 patients, 165 children (30.9%)
had heart rates below the age-specific normal awake range
during sedation (based on the published normal of Fleming
et al.) [17]. Only in 21 children (3.9% of total cohort) did
the lowest recorded heart rate fall >20% below the given
baseline average range [12]. Bradycardia (HR < 60/min), as
defined according to Pediatric Advance Life Support (PALS)
guidelines, was observed in 10 children (4.5%) mostly in
the age range of 1–3 years (Figure 2). All the patients with
bradycardiawere continuouslymonitored and assessed by the
supervising intensivist for normal blood pressure and oxygen
saturation of 95% or above. No patient required treatment.
The incidence of bradycardia was high in patients in the age
range of 1–3 years compared with the rest of the cohort. The
precise etiology of the bradycardia observed in this analysis
cannot be delineated as electrocardiogram monitoring is
known to be significantly distorted by the magnetohydrody-
namic (MHD) effect and is nondiagnostic within the bore of
any MRI magnet.
4 International Journal of Pediatrics
Table 3: Discharge times for patients with and without bradycardia according to dexmedetomidine dosing protocol.
Bradycardia Mean (st. dev.) No bradycardia Mean (st. dev.) 𝑃 value
𝑁 𝑁
Dex A 97 96.23 (29.61) 224 89.83 (22.89) 0.0597
Dex B 31 90.35 (24.01) 70 94.04 (26.32) 0.5065
Dex C 37 113.90 (41.25) 78 85.63 (31.16) 0.0005∗
All Dex 165 99.08 (32.57) 372 89.74 (25.54) 0.0012∗
Values are means (standard deviations); 𝑃 values come from Student’s 𝑡-test.
∗Significant association at 𝑃 < 0.05.
Table 4: ASA (American Society of Anesthesia) classification and sedation times according to dexmedetomidine groups.
ASAa Dex A Dex B Dex C
I 133 (41.1) 48 (46.6) 54 (46.6)
I/II 15 (4.6) 4 (3.9) 2 (1.7)
II 151 (46.6) 39 (37.9) 47 (40.5)
II/III 5 (1.5) 4 (3.9) 4 (3.5)
III 19 (5.9) 8 (7.8) 9 (7.8)
IV 1 (0.3) 0 (0) 0 (0)
Procedure time (minutes)b 40.31 (19.40) 46.42 (22.14) 57.04 (30.73)
MTD from end of test (minutes) 91.76 (25.23) 92.91 (25.57) 94.72 (37.00)
aAmerican Society of Anesthesia’ classification.
bDex A procedure time significantly shorter than Dex B and Dex C.
Distribution of heart rate by age group
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Figure 2: Heart rates for the 165 children below the age-specific
normal range. Boxes represent normal range and tick marks denote
heart rate values 20% below the normal range (15). Twenty-one
children of the entire cohort of 544 (3.9%) were beyond the lower
limit of normal by more than 20%.
Time to discharge when dexmedetomidine was used
alone was 92 ± 25 versus 94 ± 37min when additional medi-
cations were used (𝑃 = 0.46). Average discharge time among
165 children with bradycardia was longer and statistically
significant compared to the other 372 children in the study
population without bradycardia (99.08 ± 32.57min versus
89.74 ± 25.54min, 𝑃 = 0.0012, Student’s t-test). Gender was
not associated with any change in discharge time (𝑃 = 0.30)
(Table 3).
4. Discussion
Sedation is often necessary for obtaining quality MRI images
in children. The ideal drug would allow optimal imaging,
while maintaining hemodynamic and respiratory stability
[21]. As reported in previous studies, inadequate sedation
during MRI occurred in 5–15% of cases resulting in failure in
3.7%.This occurred more frequently in hyperactive, uncoop-
erative, and older children [4, 22].
Dexmedetomidine, a selective alpha 2 adrenoceptor ago-
nist, has a very safe therapeutic window with respect to
respiratory depression.This quality offers a distinct advantage
in procedural sedations, where the patient is not immediately
accessible to the medical team. There are various studies
demonstrating that dexmedetomidine is a good option for
procedural sedation [10, 12]. Interestingly, the dose used
varies greatly indicating an open debate regarding the best
dosage.
Previous studies indicate that infusion of relatively
low dose dexmedetomidine 0.1–0.7𝜇/kg/h provides effective
sedation [23–27]. In a study conducted on eight healthy
volunteers receiving dexmedetomidine infusion of 0.2–
0.6 𝜇/kg/h, the visual analog sedation scores and bispectral
index scores dropped by 30–60% [23]. However, this level of
sedation will likely not be conducive to pediatric MRI seda-
tion, where higher doses of dexmedetomidine will be needed
to accomplish the necessary sedation level. While dosing
started low in initial reports, a recent one found that higher
doses are required and have been well tolerated [12].
A variety of drugs have been used for MRI sedation. Pen-
tobarbital is a short acting barbiturate and has been used fre-
quently forMRI sedation. A comparison of pentobarbital and
chloral hydrate was performed by Rooks et al. in 498 children
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for MRI sedation [28]. No significant and demonstrable
differences were observed between the groups. Cardiovas-
cular and respiratory depressions are the common side
effects associated with pentobarbital. Several clinical trials
have compared dexmedetomidine to propofol for pediatric
procedural sedation. In a trial of 60 children undergoing
MRI, patients were randomized to receive either dexmedeto-
midine or propofol. Adequate sedation was achieved in 83%
and 90% of the patients, respectively. Onset, recovery, and
discharge time were all significantly shorter in the propofol
group. Adverse effects such as lower blood pressure and
heart rate and respiratory rate were also found more in the
propofol group [10]. Dexmedetomidine safety and efficacy
for sedation during noninvasive radiologic procedures have
been evaluated in four prospective trials [1, 8–10]. All of these
studies reported that the use of high dose dexmedetomidine
as a sole sedative resulted in high quality radiologic imaging
with less use of additional rescue medicines. Our study also
demonstrated that the use of high dose dexmedetomidine as
sole agent is effective for MRI sedation.We used fentanyl and
midazolam as rescue medicines in 117 (21.5%) of our patients
to avoid imaging artifacts, suggesting that these agentsmake a
significant contribution to the sedation strategy for a sizeable
minority of patients.
In our study, the heart rate decreased significantly from
baseline during sedation.This is an expected effect of anxioly-
sis and reflects higher baseline heart rate values from anxiety.
Other studies reported a decrease in heart rate<20% from the
baseline thatwas considered to be clinically insignificant in 86
(26%) patients [8]. To have a true comparisonwith previously
published data, we use the same definition of bradycardia;
that is, the lowest recorded heart rate during sedation fell
>20% below the given baseline average range. Using that
definition, the incidence of bradycardia in our studywas 3.9%
(21 children) in total cohort comparable to 4% as reported
by Mason et al. [12, 29]. In 4.5% of the cases, the heart rate
fell below 60 beats/min. This mostly occurred in children in
the age range of 1–3 years. More importantly, during those
periods of bradycardia, all patients maintained normal blood
pressure and normal oxygen saturation (95% or higher).
Treating bradycardia in normotensive children with gly-
copyrrolate has been reported to be associated with hyper-
tensive episode [29], which could be beneficial to children
who are hypotensive and bradycardic at the same time.
Similar to our findings, previous investigators have also
reported the occurrence of transient hypertension with bolus
administration of dexmedetomidine [30].
In our study, the occurrence of hypotension associ-
ated with high doses of dexmedetomidine was about 18%,
observed immediately after stopping the infusion or towards
the end of the procedure. None of the children needed any
intervention, consistent with observation reported in other
studies [12, 31].
Respiratory events make up a large proportion (5.5%) of
sedation complications in children [2]. In some studies, rapid
administration of large loading doses has been described to
cause respiratory complications [32–34]. A loading dose of
dexmedetomidine given over 2 minutes has been reported
to cause irregular respiration, apnea, slight hypoxemia, and
hypercapnia [35]. However, similar to ours, several other
studies have reported trivial effect of dexmedetomidine on
respiration [12, 34, 36] which is consistent with the notion
that the risk of respiratory depression is minimal with careful
dexmedetomidine sedation. Despite these supporting lines
of evidence, monitoring of respiratory function during the
administration of dexmedetomidine in those receivingmida-
zolam or fentanyl, which may depress respiratory function,
appears warranted [37].
Our reported discharge time of 92 minutes with
dexmedetomidine only and 94 minutes when additional
medicines were used is comparable to the 90 minutes’
discharge time of Heard et al. [36]. Lubisch et al. observed
a recovery time of 47 minutes [38] and Mason et al. [12]
reported recovery times ranging from 24.8 minutes to 35.2
minutes, depending on the dose of dexmedetomidine used. In
some studies, recovery time is the time lapsed until the patient
meets the discharge criteria, while in our study, like few
others, discharged time is defined as the actual time of
leaving the recovery room to go home [36]. Discharge
time of children experiencing bradycardia was longer than
that for those who did not. In our study, 165 children with
bradycardia had ameandischarge timewhichwas statistically
significant and longer than the other 372 children in the study
without bradycardia (99.08 minutes versus 89.74 minutes;
𝑃 = 0.0012). This probably could be due to the prolonged
monitoring of these patients until the bradycardia resolved.
Recovery time previously reported after sedation with
propofol for MRI has been 17 ± 8 minutes, almost half of
the recovery time when dexmedetomidine was used as a
sole agent [39]. In a second trial, forty children between the
ages of 1 and 10 years were randomized to receive either a
combination of midazolam + dexmedetomidine or propofol
only for sedation during MRI. Recovery and discharge times
were 15 minutes longer in the dexmedetomidine group. No
adverse events were recorded in either group [40]. The fast
recovery times of propofol must be weighed against the fact
that it induced deeper sedation with significant hypotension
and oxygen desaturation. Taking the results of these compar-
ison trials as a whole, dexmedetomidine appears to provide
a useful alternative to propofol for procedural sedation in
children, with a longer time of recovery but a lower incidence
of adverse effects. This is a good alternative to propofol
for patients with soy and egg white allergy and also in
institutions where use of propofol is strictly limited to be used
by anesthesiologists.
The limitations of our study include its retrospective
nature and single center experience. The current study
presents a 100% success rate of sedation with dexmedetomi-
dine for MRI. It could be asserted that the reported efficacy
is due to the use of an intensivist based specialized sedation
team rather than to dexmedetomidine itself. This is reason-
ably true to some extent as specialization and experience
should increase both success and efficiency. In spite of that,
this can be stated with confidence; much of the reported
success is specifically a function of dexmedetomidine. This
is a descriptive study and few, if any, conclusions can be
drawn about safety because the occurrence of serious seda-
tion related side effects is fortunately rare [41]. Additional
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prospective studies of the sedation for MRI in children using
a greater number of patients are warranted to provide a true
idea of safety.
In summary, high dose dexmedetomidine is an attractive
and effective medication in children for MRI sedation.When
using high dose dexmedetomidine as the only agent for
pediatric MRI, it is not unusual to observe heart rate and
blood pressure outside the established “awake” normal values.
In our experience, these changes were pretty benign and
were not associated with any adverse event. We conclude and
recommend that, from hemodynamics and respiratory per-
spective, higher dose dexmedetomidine was well tolerated
and is effective to use for successful completion of MRI, in
the majority of pediatric patients.
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